TFEB and glomerular disorder: The observations of in silico analysis and chromatin immunoprecipitation (ChIP) assays highlight that activating JAK2 encourages the binding of downstream transcription activator 1 and TFEB promoter, thus increasing the transcription activity of TFEB, achieving the purpose of reversing lysosomal dysfunction and restoring albumin permselectivity in glomerular disease (Alghamdi et al., 2017).